Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer

European Journal of Clinical Pharmacology

Volumn 70, Issue 12, 2014, Pages 1453-1463

  Ericsson, Therese ^a   Blank, Antje ^b   Von Hagens, Cornelia ^b   Ashton, Michael ^a   Äbelö, Angela ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Artesunate; Breast cancer; Dihydroartemisinin; Plasma; Population pharmacokinetics; Saliva

Indexed keywords

ARTESUNATE; DIHYDROARTEMISININ; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG SALIVA LEVEL; ENTEROHEPATIC CIRCULATION; FEMALE; HUMAN; LIMIT OF QUANTITATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SLOPE FACTOR; VOLUME OF DISTRIBUTION; ADULT; AGED; BIOLOGICAL MODEL; BLOOD; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; INTESTINE ABSORPTION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SALIVA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMALARIALS; ARTEMISININS; BREAST NEOPLASMS; FEMALE; HUMANS; INTESTINAL ABSORPTION; MIDDLE AGED; MODELS, BIOLOGICAL; SALIVA;

EID: 84922073603     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1754-2     Document Type: Article

References (58)

1. Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q, Olliaro P (2000) Pharmacokinetics of artemisinin-type compounds. Clin Pharmacokinet 39(4):255-270
2. (2010) Guidelines for the treatment of malaria, 2nd edn. World Health Organization (WHO)
3. Benakis A, Paris M, Loutan L, Plessas CT, Plessas ST (1997) Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers. Am J Trop Med Hyg 56(1):17-23
4. Price RN, Nosten F, Luxemburger C, van Vugt M, Phaipun L, Chongsuphajaisiddhi T, White NJ (1997) Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg 91(5):574-577
5. Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, McGready R, ter Kuile F, Kham A, Chongsuphajaisiddhi T, White NJ, Nosten F (1999)Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 60(4):547-555
6. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN (2007) Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369(9563):757-765
7. Efferth T (2007) Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin - from bench to bedside. Planta Med 73(4):299-309
8. Firestone GL, Sundar SN (2009) Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med 11:e32
9. Hamacher-Brady A, Stein HA, Turschner S, Toegel I, Mora R, Jennewein N, Efferth T, Eils R, Brady NR (2011) Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J Biol Chem 286(8):6587-6601
10. Singh NP, Lai H (2001) Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 70(1):49-56
11. Lai H, Nakase I, Lacoste E, Singh NP, Sasaki T (2009) Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. Anticancer Res 29(10):3807-3810
12. Singh NP, Lai HC, Park JS, Gerhardt TE, Kim BJ, Wang S, Sasaki T (2011) Effects of artemisinin dimers on rat breast cancer cells in vitro and in vivo. Anticancer Res 31(12):4111-4114
13. Mao H, Gu H, Qu X, Sun J, Song B, Gao W, Liu J, Shao Q (2013) Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro. Int J Mol Med 31(1):213-218
14. GLOBOCAN (2012) Estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer; World Health Organization (WHO)
15. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L (2011) Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J 10:263
16. Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B, Binh TQ, le Thu TA, Hung NC, Pirmohamed M, Park BK, Edwards G (2002) Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos 30(9):1005-1012
17. Na-Bangchang K, Krudsood S, Silachamroon U, Molunto P, Tasanor O, Chalermrut K, Tangpukdee N, Matangkasombut O, Kano S, Looareesuwan S (2004) The pharmacokinetics of oral dihydroartemisinin and artesunate in healthy Thai volunteers. Southeast Asian J Trop Med Public Health 35(3):575-582
18. Newton P, Suputtamongkol Y, Teja-Isavadharm P, Pukrittayakamee S, Navaratnam V, Bates I, White N (2000) Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob Agents Chemother 44(4):972-977
19. Teja-Isavadharm P, Watt G, Eamsila C, Jongsakul K, Li Q, Keeratithakul G, Sirisopana N, Luesutthiviboon L, Brewer TG, Kyle DE (2001) Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria. Am J Trop Med Hyg 65(6):717-721
20. Hassan Alin M, Ashton M, Kihamia CM, Mtey GJ, Bjorkman A (1996) Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg 90(1):61-65
21. Ashton M, Hai TN, Sy ND, Huong DX, Van Huong N, Nieu NT, Cong LD (1998) Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab Dispos 26(1):25-27
22. Ashton M, Nguyen DS, Nguyen VH, Gordi T, Trinh NH, Dinh XH, Nguyen TN, Le DC (1998) Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther 63(4):482-493
23. Khanh NX, de Vries PJ, Ha LD, van Boxtel CJ, Koopmans R, Kager PA (1999) Declining concentrations of dihydroartemisinin in plasma during 5-day oral treatment with artesunate for Falciparum malaria. Antimicrob Agents Chemother 43(3):690-692
24. van Agtmael MA, Cheng-Qi S, Qing JX, Mull R, van Boxtel CJ (1999) Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents 12(2):151-158
25. Simonsson US, Jansson B, Hai TN, Huong DX, Tybring G, Ashton M (2003) Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther 74(1):32-43
26. Svensson US, Ashton M, Trinh NH, Bertilsson L, Dinh XH, Nguyen VH, Nguyen TN, Nguyen DS, Lykkesfeldt J, Le DC (1998) Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 64(2):160-167
27. Asimus S, Hai TN, Van Huong N, Ashton M(2008) Artemisinin and CYP2A6 activity in healthy subjects. Eur J Clin Pharmacol 64(3):283-292
28. Elsherbiny DA, Asimus SA, Karlsson MO, Ashton M, Simonsson US (2008) A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn 35(2):203-217
29. Birgersson S, Ericsson T, Blank A, von Hagens C, Ashton M (2014) A high-throughput liquid chromatographic-tandem mass spectrometric assay for quantification of artesunate and its metabolite dihydroartemisinin in human plasma and saliva. Bioanalysis. doi: 10.4155/BIO.14.116
30. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ. NONMEM user's guides (1989-2009), ICON Development Solutions, Ellicott City, MD, USA
31. Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Prog Biomed 75(2):85-94
32. Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Prog Biomed 79(3):241-257
33. Jonsson EN, Karlsson MO (1999) Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Prog Biomed 58(1):51-64
34. Beal SL, Sheiner LB (1982) Estimating population kinetics. Crit Rev Biomed Eng 8(3):195-222
35. Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28(5):481-504
36. Ahn JE, Karlsson MO, Dunne A, Ludden TM (2008) Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 35(4):401-421
37. Bergstrand M, Karlsson MO (2009) Handling data below the limit of quantification in mixed effect models. AAPS J 11(2):371-380
38. Lee IS, Hufford CD (1990) Metabolism of antimalarial sesquiterpene lactones. Pharmacol Ther 48(3):345-355
39. Batty KT, Le AT, Ilett KF, Nguyen PT, Powell SM, Nguyen CH, Truong XM, Vuong VC, Huynh VT, Tran QB, Nguyen VM, Davis TM (1998) A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria. Am J Trop Med Hyg 59(5):823-827
40. Gordi T, Xie R, Huong NV, Huong DX, Karlsson MO, Ashton M (2005) A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br J Clin Pharmacol 59(2):189-198
41. Shepard TA, Reuning RH, Aarons LJ (1985) Estimation of area under the curve for drugs subject to enterohepatic cycling. J Pharmacokinet Biopharm 13(6):589-608
42. Pétricoul O, Cosson V, Fuseau E, Marchand M (2007) Population models for drug absorption and enterohepatic recycling. In: Ette EI, Williams PJ (eds) Pharmacometrics: the science of quantitative pharmacology. John Wiley & Sons, Hoboken, pp 345-382
43. Tan B, Naik H, Jang IJ, Yu KS, Kirsch LE, Shin CS, Craft JC, Fleckenstein L (2009) Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects. Malar J 8:304
44. Morris CA, Onyamboko MA, Capparelli E, Koch MA, Atibu J, Lokomba V, Douoguih M, Hemingway-Foday J, Wesche D, Ryder RW, Bose C, Wright L, Tshefu AK, Meshnick S, Fleckenstein L (2011) Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. Malar J 10:114
45. Davies NM, Takemoto JK, Brocks DR, Yanez JA (2010) Multiple peaking phenomena in pharmacokinetic disposition. Clin Pharmacokinet 49(6):351-377
46. Keiser J, Gruyer MS, Perrottet N, Zanolari B, Mercier T, Decosterd L (2009) Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciola hepatica. J Antimicrob Chemother 63(3):543-549
47. Li Q, Xie L, Zhang J, Weina PJ (2008) The distribution pattern of intravenous [(14)C] artesunate in rat tissues by quantitative whole-body autoradiography and tissue dissection techniques. J Pharm Biomed Anal 48(3):876-884
48. Le Thi DT, Le NH, Nguyen CH, Phan Thi D, Na-Bangchang K (2008) Pharmacokinetics of a five-day oral dihydroartemisinin monotherapy regimen in patients with uncomplicated falciparum malaria. Drug Metab Pharmacokinet 23(3):158-164
49. Diem Thuy LT, Ngoc Hung L, Danh PT, Na-Bangchang K (2008) Absence of time-dependent artesunate pharmacokinetics in healthy subjects during 5-day oral administration. Eur J Clin Pharmacol 64(10):993-998
50. Leskovac V, Theoharides AD (1991) Hepatic metabolism of artemisinin drugs - I. Drug metabolism in rat liver microsomes. Comp Biochem Physiol C 99(3):383-390
51. Liu T, Du F, Wan Y, Zhu F, Xing J (2011) Rapid identification of phase I and II metabolites of artemisinin antimalarials using LTQ-Orbitrap hybrid mass spectrometer in combination with online hydrogen/deuterium exchange technique. J Mass Spectrom 46(8):725-733
52. Asimus S, Elsherbiny D, Hai TN, Jansson B, Huong NV, Petzold MG, Simonsson US, Ashton M (2007) Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam Clin Pharmacol 21(3):307-316
53. von Bahr C, Steiner E, Koike Y, Gabrielsson J (1998) Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism. Clin Pharmacol Ther 64(1):18-26
54. Aps JK, Martens LC (2005) Review: the physiology of saliva and transfer of drugs into saliva. Forensic Sci Int 150(2-3):119-131
55. Gordi T, Hai TN, Hoai NM, Thyberg M, Ashton M (2000) Use of saliva and capillary blood samples as substitutes for venous blood sampling in pharmacokinetic investigations of artemisinin. Eur J Clin Pharmacol 56(8):561-566
56. Batty KT, Ilett KF, Davis TM (2004) Protein binding and alpha: beta anomer ratio of dihydroartemisinin in vivo. Br J Clin Pharmacol 57(4):529-533
57. Jusko WJ, Milsap RL (1993) Pharmacokinetic principles of drug distribution in saliva. Ann N YAcad Sci 694:36-47
58. Posti J (1982) Saliva-plasma drug concentration ratios during absorption: theoretical considerations and pharmacokinetic implications. Pharm Acta Helv 57(3):83-92